TalkMed Group Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for TalkMed Group.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Healthcare earnings growth	18.9%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

No updates

Recent updates

TalkMed Group (SGX:5G3) Seems To Use Debt Quite Sensibly

Sep 26

Unpleasant Surprises Could Be In Store For TalkMed Group Limited's (SGX:5G3) Shares

Apr 08

TalkMed Group's (SGX:5G3) Solid Earnings Have Been Accounted For Conservatively

Mar 01

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as TalkMed Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

SGX:5G3 - Analysts future estimates and past financials data (SGD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2024	79	28	34	34	N/A
3/31/2024	81	30	37	38	N/A
12/31/2023	84	32	41	42	N/A
9/30/2023	83	31	42	43	N/A
6/30/2023	82	31	44	45	N/A
3/31/2023	79	31	40	41	N/A
12/31/2022	77	31	37	37	N/A
9/30/2022	70	28	32	32	N/A
6/30/2022	64	26	26	26	N/A
3/31/2022	63	26	24	25	N/A
12/31/2021	61	25	22	23	N/A
9/30/2021	62	25	21	23	N/A
6/30/2021	60	23	22	24	N/A
3/31/2021	61	23	26	28	N/A
12/31/2020	62	23	29	31	N/A
9/30/2020	67	27	32	33	N/A
6/30/2020	71	31	36	37	N/A
3/31/2020	74	34	34	34	N/A
12/31/2019	76	36	34	36	N/A
9/30/2019	73	34	32	37	N/A
6/30/2019	71	33	28	34	N/A
3/31/2019	66	31	28	33	N/A
12/31/2018	61	29	26	30	N/A
9/30/2018	58	28	27	27	N/A
6/30/2018	55	27	27	27	N/A
3/31/2018	57	29	N/A	30	N/A
12/31/2017	61	32	N/A	31	N/A
9/30/2017	65	34	N/A	38	N/A
6/30/2017	68	35	N/A	41	N/A
3/31/2017	69	37	N/A	40	N/A
12/31/2016	69	37	N/A	45	N/A
9/30/2016	68	37	N/A	42	N/A
6/30/2016	67	36	N/A	40	N/A
3/31/2016	66	36	N/A	40	N/A
12/31/2015	66	37	N/A	40	N/A
9/30/2015	65	38	N/A	40	N/A
6/30/2015	65	40	N/A	41	N/A
3/31/2015	65	40	N/A	40	N/A
12/31/2014	63	39	N/A	28	N/A
9/30/2014	61	32	N/A	39	N/A
6/30/2014	59	31	N/A	29	N/A
3/31/2014	58	30	N/A	27	N/A
12/31/2013	56	28	N/A	36	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 5G3's forecast earnings growth is above the savings rate (2.2%).

Earnings vs Market: Insufficient data to determine if 5G3's earnings are forecast to grow faster than the SG market

High Growth Earnings: Insufficient data to determine if 5G3's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 5G3's revenue is forecast to grow faster than the SG market.

High Growth Revenue: Insufficient data to determine if 5G3's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 5G3's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/26 13:25
End of Day Share Price	2024/12/26 00:00
Earnings	2024/06/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

TalkMed Group Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Siew Khee Lim	CGS International
Jarick Seet	RHB Investment Bank

TalkMed Group Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Tamarind Health Limited entered into an implementation agreement to acquire TalkMed Group Limited (SGX:5G3) from Ladyhill Holdings Pte. Ltd.,Ang Peng Tiam, Khoo Kei Siong, Lim Hong Liang and Teo Cheng Peng for approximately SGD 600 million.

TalkMed Group (SGX:5G3) Seems To Use Debt Quite Sensibly

Upcoming dividend of S$0.023 per share

First half 2024 earnings released: EPS: S$0.006 (vs S$0.009 in 1H 2023)

First half dividend of S$0.023 announced

Upcoming dividend of S$0.013 per share

TalkMed Group Limited Approves Final One-Tier Tax-Exempt Dividend for the Financial Year Ended 31 December 2023

Unpleasant Surprises Could Be In Store For TalkMed Group Limited's (SGX:5G3) Shares

Final dividend reduced to S$0.013

TalkMed Group Limited, Annual General Meeting, Apr 18, 2024

Full year 2023 earnings released

Talkmed Group Limited Proposes Tax Exempt (One-Tier) Final Dividend for the Financial Year Ended 31 December 2023, Payable on 10 May 2024

TalkMed Group Limited Announces Management Changes

TalkMed Group Limited Appoints Lam Kok Shang as Independent Non-Executive Director, Chairman of the Audit and Risk Committee, Member of the Nominating Committee, Effective January 1, 2024

First half 2023 earnings released: EPS: S$0.011 (vs S$0.009 in 1H 2022)

TalkMed Group Limited Approves the Final One-Tier Tax-Exempt Dividend in Respect of 2022

Upcoming dividend of S$0.015 per share at 7.0% yield

Full year 2022 earnings released: EPS: S$0.023 (vs S$0.019 in FY 2021)

TalkMed Group's (SGX:5G3) Solid Earnings Have Been Accounted For Conservatively

Full year 2022 earnings released

Insufficient new directors

TalkMed Group Limited Announces Tax Exempt (One-Tier) Interim Cash Dividend, Payable on 22 August 2022

First half 2022 earnings released

Insufficient new directors

Insufficient new directors

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

TalkMed Group Limited, Annual General Meeting, Apr 21, 2022

Insufficient new directors

Full year 2021 earnings: Revenues exceed analyst expectations

TalkMed Group Limited Proposes Final Dividend, Payable on 11 May 2022

Joint Company Secretary Lingna Dai has left the company

New 90-day low: S$0.40

TalkMed Group Limited, Annual General Meeting, Apr 20, 2021

Full year 2020 earnings released

Revenue beats expectations, earnings disappoint

New 90-day high: S$0.46

New 90-day low: S$0.38

First half earnings released

New 90-day low - S$0.38

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources